Cancer Immunotherapy and Delivery System: An Update.
Cancer Immunotherapy and Delivery System: An Update.
复制标题
癌症免疫治疗和递送系统：更新。
DOI：
10.3390/pharmaceutics14081630
复制
发表时间：
2022-08-04
期刊：
影响因子：
5.4
通讯作者：
Li, Guangfu
中科院分区：
文献类型：
--
作者：
Yang, Ming;Olaoba, Olamide Tosin;Zhang, Chunye;Kimchi, Eric T.;Staveley-O'Carroll, Kevin F.;Li, Guangfu
关键词：
随着对肿瘤微环境中免疫力的理解，免疫疗法成为临床治疗许多癌症的有力工具。应用于癌症免疫治疗的策略主要包括免疫检查点的阻断、工程化细胞（如T细胞、自然杀伤细胞和巨噬细胞）的过继转移、细胞因子治疗、癌症疫苗和溶瘤病毒治疗。许多因素，如产品价格，脱靶副作用，免疫抑制肿瘤微环境和癌细胞异质性，影响免疫疗法对癌症的治疗效果。此外，一些治疗方法，如嵌合抗原受体（CAR）T细胞疗法，在治疗淋巴瘤、白血病和多发性骨髓瘤患者方面比实体瘤更有效。为了提高靶向免疫疗法的功效并减少脱靶效应，在过去几十年中已经使用诸如纳米颗粒、水凝胶基质和可植入支架的工具开发了用于免疫疗法的递送系统。本文首先综述了目前常用的免疫治疗方法及其局限性。然后，它概述了可以应用于提高治疗效果和最大限度地减少副作用的相对输送系统。本文还讨论了这些递送系统在癌症免疫治疗中应用的挑战、前沿和前景。最后，这些方法在临床试验中的应用进行了综述。
With an understanding of immunity in the tumor microenvironment, immunotherapy turns out to be a powerful tool in the clinic to treat many cancers. The strategies applied in cancer immunotherapy mainly include blockade of immune checkpoints, adoptive transfer of engineered cells, such as T cells, natural killer cells, and macrophages, cytokine therapy, cancer vaccines, and oncolytic virotherapy. Many factors, such as product price, off-target side effects, immunosuppressive tumor microenvironment, and cancer cell heterogeneity, affect the treatment efficacy of immunotherapies against cancers. In addition, some treatments, such as chimeric antigen receptor (CAR) T cell therapy, are more effective in treating patients with lymphoma, leukemia, and multiple myeloma rather than solid tumors. To improve the efficacy of targeted immunotherapy and reduce off-target effects, delivery systems for immunotherapies have been developed in past decades using tools such as nanoparticles, hydrogel matrix, and implantable scaffolds. This review first summarizes the currently common immunotherapies and their limitations. It then synopsizes the relative delivery systems that can be applied to improve treatment efficacy and minimize side effects. The challenges, frontiers, and prospects for applying these delivery systems in cancer immunotherapy are also discussed. Finally, the application of these approaches in clinical trials is reviewed.
登录
查看更多内容
影响因子：
13.6
作者：
Chen ZG
通讯作者：
Chen ZG
影响因子：
7.3
作者：
Balakrishnan PB;Sweeney EE
通讯作者：
Sweeney EE
影响因子：
17.1
作者：
Alghamri, Mahmoud S.;Banerjee, Kaushik;Mujeeb, Anzar A.;Mauser, Ava;Taher, Ayman;Thalla, Rohit;McClellan, Brandon L.;Varela, Maria L.;Stamatovic, Svetlana M.;Martinez-Revollar, Gabriela;V. Andjelkovic, Anuska;V. Gregory, Jason;Kadiyala, Padma;Calinescu, Alexandra;Jimenez, Jennifer A.;Apfelbaum, April A.;Lawlor, Elizabeth R.;Carney, Stephen;Comba, Andrea;Faisal, Syed Mohd;Barissi, Marcus;Edwards, Marta B.;Appelman, Henry;Sun, Yilun;Gan, Jingyao;Ackermann, Rose;Schwendeman, Anna;Candolfi, Marianela;Olin, Michael R.;Lahann, Joerg;Lowenstein, Pedro R.;Castro, Maria G.
通讯作者：
Castro, Maria G.
影响因子：
4.6
作者：
Berti, Cristiana;Graciotti, Michele;Klok, Harm-Anton
通讯作者：
Klok, Harm-Anton
DOI：
10.1017/s0266462322000356
发表时间：
2022-07-11
影响因子：
3.2
作者：
Carey, Niamh;Leahy, Joy;Barry, Michael
通讯作者：
Barry, Michael